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Abstract: Hepatitis B virus (HBV) infection is a serious global public health problem and responsible for most 
common liver infection worldwide. The infection if contracted early in life, may lead to chronic liver disease, 
including cirrhosis and hepatocellular carcinoma. The aim of this study was to determine Hepatitis B Surface 
Antigenemia (HBsAg) and risk factors of transmission among apparently healthy asymptomatic individual 
volunteers in Jos metropolis. In order to estimate and further evaluate prevalence rate of HBsAg in our population of 
study, a well-structured questionnaire was used to obtain the social and demographic information of consenting 
participants, while ethical approval was sought and obtained. Two hundred (200) volunteer subjects were enrolled 
for the study, three milliliter (3ml) of venous blood samples were collected aseptically by venipuncture.Sera 
obtained were assayed for the HBsAg using the HBsAg test strip (Acon Laboratory incorporated 
USA).Confirmatory tests were performed for Serum HBsAg by using a third generation enzyme linked 
Immunosorbent assay (HBsAg ELISA)-(Bio-Rad Laboratories, Incorporated California, USA). Overall results 
showed a prevalence of 45(22.5%) positivity among subjects screened. considering gender 25 (12.5%) were males 
while 20 (10.0%) were females,(p = 0.020),Age distribution showed that subjects aged 25-29 years recorded a 
prevalence of 10(12.5%);(p = 0.001), this is relatively high in view of the fact that the study subjects were a 
apparently healthy population. Clinical risk factors showed that  2.5% of sero-positive subject had a history of blood 
transfusion(p = 0.480),while4.5% had a record of previous STD infection (p = 0.423).Serological markers among 
the apparently healthy individuals screened showed; 40 (20.0%), 29 (14.5%), 8 (4.0%), 20 (10.0%) and 38 (19.0%) 
for HBsAg, Anti HBs, HBeAg, Anti HBe and Anti HBc respectively (P< 0.005).Changes in liver enzymes among 
subjects that tested positive for the HBV showed that. the apparently healthy individuals recorded an abnormality of 
13(28.9%) respectively, [P= 0.0144;( P<0.005)]. This study however confirms the presence of Hepatitis B surface 
antigenemia among apparently healthy individuals in our study locations. This calls for mass immunization and 
public health education on the dangers of this infectious agent in the population. 
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2.0 Introduction 
Hepatitis B virus (HBV) has been described as a 
major public health concern, occurring endemically, 
in all areas of the world (Maddrey et al., 2000). 
Chronic hepatitis is characterized by the presence of 
HBsAg in the blood for a period above six months. 
Although chronic hepatitis B carriers may remain 
asymptomatic as the infection remains inactive, this 
could actually progress to liver fibrosis, cirrhosis and 
hepatocellular carcinoma (HCC). Yang et al., 
reported that cirrhosis is present in majority of 
hepatitis B patients and chronic viral hepatitis is said 
to play a major role in activating liver fibrosis 
(Budhu, 2006 and Yang, 2011).HCC is reported to be 
the “third leading cause of cancer-related death in the 
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viral hepatitis of which HBV is inclusive (Yang, 
2011). 
 
Based on the prevalence of HBV chronic carriers 
amongst adults in the general population, Countries 
are classified as having low endemicity (< 2%), 
intermediate endemicity (2%–5%), or high 
endemicity (> 5%) of infection (Hall, 1994). 
Hepatitis B is highly endemic in developing nations 
with large population such as South East Asia,China, 
sub-Saharan Africa and the Amazon basin (Sharma et 
al., 2005), with at least 8.0% of the population 
assuming HBV chronic carrier  status.(Alter, 2003). 
In Eastern and Southern Europe, the Middle East, 
Japan, and part of South America, mixed pattern of 
transmission exist, including transmission among 
infants, early childhood and adult transmission (Lok, 
2005).  
 
The endemicity of HBV is low in most developed 
countries, such as North America, Northern and 
Western Europe and Australia. In these regions, HBV 
infects 5.0-7.0% of the population, and only 0.5-2.0% 
of the population become chronic carriers. In these 
areas, most HBV infections occurs in adolescents and 
young adults in relatively well defined high-risk 
groups, comprising injection drug users, homosexual 
males, health-care workers, blood transfusion or 
hemodialysis patients (WHO, 1998). In Africa, 
hepatitis B virus infection is the most common cause 
of liver disease which is the third most common 
cause of death in medical wards with 15-60% 
seropositivity for HBsAg in normal population 
(Bojuwoye, 1997; Ugwuja and Ugwu, 2010). 
 
HBV infections constitute a major public health 
concern in Nigeria while several reports have 
established the endemicity of HBV by the presence 
of HBsAg in different groups of population studied 
from different parts of the country,(Olubuyide,1997). 
The evaluation of the data on the prevalence of the 
HBsAg provided an idea on its prevalent rate in the 
community (Bhattacharya et al., 2007; Afsar et al., 
2010). HBV are blood borne pathogens that can be 
transmitted through blood transfusion and could pose 
a huge problem in areas where mechanisms of 
ensuring blood safety are uncertain (Umolu et al., 
2005).  
 
A study carried out on one hundred (100) healthy 
blood donors in Benin City showed a prevalence of 
11.0%, compared to the report from a study 
conducted in Central Hospital, Warri where a 
prevalence of 12.0% was recorded. Similarly, a 
prevalence of 4.4% was reported in another study 
carried out in Lagos among healthy pregnant women. 
The prevalence of HBV varies between 2% in 
developed countries where the prevalence is low to 
about 8% in developing countries where infection is 
endemic with sex, age and socio-economic status as 
important risk factors for infection (Odusanya et al., 
2005; Alikor and Erhabor, 2007) 
 
HBV is found in highest concentrations in the blood, 
and lower concentrations in saliva, semen, vaginal 
secretions, and wound exudates. The virus can 
remain viable for >7 days on environmental surfaces 
at room temperature (CDC, 2008). Sexual activity, 
especially heterosexual, and injection-drug use 
account for the majority of HBV transmission in low-
prevalence areas (Seeger et al., 2000) while perinatal 
transmission account for the majority of the 
transmission in high prevalence areas (Harry et al., 
1994).However, HCC might be prevented by early 
detection and therapy (Xuan et al.,2007).  
 
The prevalence of HBV infection also varies 
markedly from one region of the world to another. 
Racial differences between populations, cultural and 
economic differences in developing countries like 
Nigeria are factors considered responsible for the 
differences. The global burden of Hepatitis B remains 
enormous, due largely to lack of universal HBV 
vaccination (Alexander and Kowdley, 2006).The 
prevalence observed from previous studies demands 
for a routine use of  Serological markers for HBV 
screening in blood banks and antennal clinics. These 
tests are obligatory for transfusion safety and may 
give an idea about the seropositivity rates of a 
specific region (Afsar et al., 2010).  
 
3.0 Materials and Methods 
3.1 Study area: The study was carried out in 
some parts of Plateau State. This comprises of Jos 
metropolis comprising parts of Jos South and Jos 
North, Local Government areas. The selection of 
these communities was as a result of preliminary 
investigations conducted among amongst families 
with symptoms suspected to be an indicator for the 
HBV. 
 
3.2 Ethical consideration: Informed consent of 
each participant was obtained prior to testing. Ethical 
approval for this research work was sought and 
obtained from relevant authorities. 
 
3.3 Study Population: Subjects studied 
include; Two Hundred (200) apparently Healthy 
Individuals. The study included subjects of all sex, 
aged 3 to 60 years. 
Inclusion and Exclusion criteria: Subjects who 
gave informed consent and are asymptomatic by 
routine screening, were included in the study, 
subjects who had once been vaccinated with the 
required three doses of the vaccine and those who 
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3.4 Collection and processing of specimens: 
Three milllilitre (3ml) of blood samples were 
collected aseptically by venipuncture using Syringe 
and needle. Each blood sample was transferred from 
the syringe into a carefully labelled plastic microtitre 
tube containing ethylene diamine tetraacetic acid 
(EDTA) and stored in the refrigerator at 4oC.Each 
resultant supernatant (Plasma) was carefully decanted 
into a new labelled tube  and stored at -20°C until 
ready for use. 
 
3.5      laboratory analysis: Assay of collected 
sample was carried out first by  carrying out an On-
the-spot testing for HBsAg  using the HBsAg test 
strip (Acon Laboratory incorporated USA), according 
to the manufacturer’s instructions. Confirmatory tests 
were then performed with Monolisa HBsAg ULTRA 
assay (HBsAg ELISA test reagent)(Biorad 
Laboratories,USA) which is a one-step enzyme 
Immunoassay according to the manufacturer’s 
instructions. 
 
Hepatitis B Surface Antigen (HBsAg) 
Detection:HBsAg test strip manufactured by Acon 
laboratory incorporated USA was used for the 
preliminary screening. The HBsAg one step hepatitis 
B surface antigen test strip is a rapid 
chromatographic immune assay for the qualitative 
detection of hepatitis B surface antigen in serum or 
plasma. The test was carried out and interpreted 
according to the manufacturer’s instructions.   
 
Confirmation by ELISA:HBsAg ELISA test 
reagent manufactured by Biorad Laboratories was 
used for the confirmatory screening.Monolisa HBsAg 
ULTRA assay is a one-step enzyme Immunoassay 
technique of the “Sandwich” type for the detection of 
the surface antigen of the Hepatitis B virus (HBsAg) 
in the serum or plasma. 
 
Screening using the 5-panel test kits for 
Serological markers: HBV-5 panel test for the 
qualitative assessment of the markers of hepatitis B 
virus infection in human serum, plasma and whole 
blood. The HBV Panel Test is an 
Immunochromatographic assay method to quickly 
detect five major markers of HBV infections, 
HBsAg, Anti-HBs (HBsAb), Anti-HBc (HBcAb), 
HBeAg and Anti-HBe (HBeAb) in human blood 
specimens. 
 
Liver Enzyme determination among seropositive 
individuals: All the HBsAg positive samples were 
assayed for alanine aminotransferase (ALT). 
 
Results 
From the tables below, out of the  Two- Hundred 
(200) subjects screened a prevalence of 45(22.5%) 
positivity was recorded, considering gender 25 
(12.5%) were males while 20 (10.0%) were females. 
Individuals aged 25-29 years recorded a prevalence 
of 5.0% compared to the 3.5% prevalent recorded 
among subjects aged 30-34 years, (Table 1). Risk 
factors among Apparently Healthy subjects showed 
that 10(5.0%) of subjects that tested positive had 
history of alcoholic consumption while 9(4.5) % of 
the subjects screened had history of Sexually 
Transmitted Disease (STD), (Table 2).Furthermore, 
history of hepatitis infection in the family which 
recorded a prevalence of 3.0%.(Table 3).Response to 
serological markers showed that the highest rate of 
positivity recorded with the HBsAg had 20% 
positivity, the HBeAg recorded 4.0% positivity, 
while Anti-HBs which indicates antibody to the 
HBsAg showed 14.5% positivity among the subjects 
screened. Anti-HBe positivity recorded 
10.0%.However,Anti-HBc Positivity showed a 
positivity of 19.0 % (Table 4).The positive subjects 
screened, recorded an ALT abnormality of 
28.9%.(Table 5). 
Table 1: Distributions of Apparently Healthy Subjects Screened Based On Sex and Age 
Total Number       No. Pos. (%)    No. Neg. (%)   P-value       OR       95% C.I 
Examined. (%)  
 
Sex        
   Male  110(55.0)         25(12.5)               85(42.5)          0.020 1   
   Female  90(45.0)          20(10.0)         70(35.0)   1.03 0.53-2.01 
 
Age        
25-29  35(17.5)          10(5.0)                  25(12.5)                      1.24   
30-34  30(15.0)             7(3.5)          23(12.0)   0.94   
35-39  30(15.0)              6(3.0)          24(16.5)   0.77   
40-44  36(18.0)              6(3.0)          30(15.0)   0.62  
45-49  24(12.0)            5(2.5)          19(9.5)   0.81 
50-54  20(10.0)            4(2.0)          16(8.0)   1 
55-59  15(7.5)            4(2.0)          11(5.5)   0.81 
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Table 2 : Distributions of Apparently Healthy Subjects Screened Based on Clinical  Risk Factors 
 
History of Blood transfusion 
Yes                 21(10.5)                       5(2.5)          16(8.0)     1 
No    179(89.5)                   40(20.0)          139(69.5)  0.480   1.09 0.38-3.15 
 
History of STD Infection 
Yes                 15(7.5)                       9(4.5)               6(3.0)      1 
No    185(92.5)                   36(18.0)          149(74.5)  0.423    6.21 
 
History of jaundice in the Family 
Yes                 10(5.0)                       4(2.0)               6(3.0)      1 
No    179(95.0)                   40(20.5)          149(74.5)  0.534    2.42 
 
 
Table 3: Distributions of Apparently Healthy Subjects Screened Based on other Risk Factors 
 
Total Number       No. Pos. (%)    No. Neg. (%)   P-value       OR       95% C.I 
Examined. (%)  
 
History of Hepatitis infection in the Family 
Yes                 46(23.0)                       6(3.0)          40(20.0)          1 
No   154(77.0)                   39(19.5)          115(57.5)  0.312         0.44  
 
Previous Infection with HBV 
Yes                     9(4.5)                       5(2.5)               4(2.0)           1 
No    191(95.5)                   40(20.0)          151(74.5)    0.542           4.72 
 
Awareness of HBV as an Infectious Agent 
Yes                 70(35.0)                       4(2.0)               66(33.0)            1 
             0.1275       0.13 
 
History of Alcoholic Consumption 
Yes                 30(15.0)                       4(2.0)               6(3.0)              1 
No    170(85.0)                   30(15.0)          140(70.0)        0.428        2.33 
 
 
Table 4: Overall Prevalence of HBV markers among Positive subjects screened 
 
 
Table 5: Overall Determination Of Serum Alanine Aminotransferase (Alt) Levels On Positive Subjects 
Screened 
 
Total Number       No. Pos. (%)    No. Neg. (%)   P-value       OR       95% C.I 
Examined. (%)  
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Discussion 
Screening asymptomatic people is an important 
instrument in disease detection, prompt diagnosis and 
intervention especially in silent killers like HBV. 
This study therefore set out to determine the 
seroprevalence of HBsAg in an apparently healthy 
population. Of the 200 subjects screened a prevalence 
of the 45(22.5%) positivity was recorded, considering 
gender 25 (12.5%) were males while 20 (10.0%) 
were females, for HBsAg, this is relatively high in 
view of the fact that the study subjects apparently 
healthy population.  
In comparison to studies from other parts of the 
country, the prevalence of infection reported in this 
study was higher than previous studies conducted in 
different parts of the country, such as 4.9 and 10.3% 
reported in Port Harcourt and Jos respectively (Ejele 
and Ojule, 2004; Sirisena et al, 2002),In a similar 
study conducted by Akani et al. (2005) among 
pregnant women in Port Harcourt a low prevalence of 
4.3% was recorded, while a prevalence of 21.3%  
was recorded in a study conducted  at Ibadan 
(Otegbayo et al, 2003) and 17.1%  prevalence 
recorded among sex workers in Nasarawa state 
(Nneka, 2007). However a slightly higher prevalent 
rate was recorded in one of the two studies conducted 
in Jos,with a record of 23.9% and 15.1% prevalence 
(Uneke et al, 2005; Egah et al, 2007).These 
differences might not be unconnected with the fact 
that some of the studies were not from the same risk 
group.    
Individuals aged 25-29 years recorded a prevalence 
of 5.0% compared to the 3.5% prevalent recorded 
among subjects aged 30-34 years. Chang, (2007) and 
Uneke et al,(2005) found that  this age group 
comprises the sexually active group,which support 
the role of sexual transmission of the virus (Dawaki 
and Kawo 2006).However, there was no statistical 
significant association between the viral infection and 
age. Similarly there was no significant association 
between gender and viral infection (P> 0.05) 
although the prevalence was higher (12.5%) among 
the males.  
It was observed from this study that more males 
(12.5%) were infected with HBV than females 
(10.0%) while more females, However Bwogi et al. 
(2009) in his study reported a lower prevalence of 
HBV in men than in female and suggested the 
interplay of circumcision as protective. This was not 
the case in this study even though it was in an area 
that male circumcision is mandatory.  
Risk factors among Apparently Healthy subjects 
showed that 10(5.0%) of subjects that tested positive 
had history of alcoholic consumption, Alcohol 
remains the single most significant cause of liver 
disease throughout the Western world and is 
responsible for between 40 and 80% of cases of 
cirrhosis in different countries. Several studies in 
urban areas have reported that alcoholics have an 
increased prevalence of hepatitis B infection 
(Jacobson et al, 1992). 
Similarly, not only may alcoholics have an increased 
risk of contracting hepatitis B, but once infected, 
hepatitis B may occasionally exacerbate liver disease 
in these patients. Several studies have reported that 
alcoholic patients with advanced liver disease 
(cirrhosis) have a higher prevalence of hepatitis B 
markers than alcoholics with less severe forms of 
alcoholic liver disease (Jacobson et al, 1992). Hence 
Abuse in alcohol consumption may favor the 
development of HBV chronic infection because 
alcohol can compromise the immune system (Laskus 
et al, 1988). 
This study showed that 9(4.5%) of the subjects 
screened had history of Sexually Transmitted Disease 
(STD).Busch (2000) and Lee et al,(2006) confirmed 
that sexual and prenatal HBV transmission usually 
results from mucous membrane exposures to 
infectious blood and body fluids. Saravanan et al, 
(2007) reported that HBsAg had been found in all 
body secretions and excretions. However, only blood, 
vaginal and menstrual fluids, and semen has been 
shown to be infectious.  
There were no statistically significant differences 
with respect to contact with patient who had history 
of jaundice with a prevalence of 2.0%.History of 
hepatitis B infection in the family recorded a 
prevalence of 3.0%, Kuhns (2004) reported that HBV 
infection may also be transmitted between household 
contacts and between sexual partners, either 
homosexual or heterosexual, and in toddler-aged 
children in groups with high HBsAg carrier rate.   
The findings of this study indicated 5% of HBV 
positive cases were alcoholic consumers while 4% 
are due to STD. However, Lee et al,(2006) asserts 
that the major risk factor for both HBV infections is 
parenteral exposure. HBV is stable on environmental 
surfaces for at least 7 days, and indirect inoculation 
of HBV can occur via inanimate objects like 
toothbrushes, baby bottles, and toys, razors, eating 
utensils, hospital equipment and other objects, by 
contact with mucous membranes or open skin breaks 
(Pan and Zhang, 1996). In this study there were no 
statistically significant differences with respect to 
method of nail trimming, method of ear piercing, 
shaving and subjects with history of blood 
transfusion. 
Serologic testing for the diagnosis of hepatitis B virus 
(HBV) infection involves measurement of a panel of 
distinct HBV-specific antigens and host antibodies 
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general, the panel of responses can determine 
whether a patient is susceptible to infection, immune 
as a result of resolved infection, immune as a result 
of vaccination, acutely infected, or chronically 
infected. 
Patients who develop chronic (persistent) HBV 
infection have a serologic response in the acute phase 
of HBV infection that is similar to patients who 
subsequently resolve the HBV infection. With 
chronic (persistent) HBV infection, HBsAg and anti-
HBc (IgG antibodies) generally persist for life, 
(Weinbaum, 2008). The diagnosis of acute HBV 
infection is established by a characteristic serologic 
profile. During acute infection, the appearance of 
Virologic markers and host antibody responses 
develop in a typical pattern (Mast et al., 2006). The 
first serologic marker to appear is hepatitis B surface 
antigen (HBsAg), which can initially be detected in 
serum from 1 to 12 weeks (average, 30 to 60 days) 
after infection. 
From this study the highest rate of positivity recorded 
involved the HBsAg with 20% among the apparently 
healthy subjects, According to (Lee, 2010). The 
presence of HBsAg for longer than 6 months after 
acute infection indicates chronic infection. The 
detection of HBsAg and absence of IgM anti-HBc in 
a single serum specimen also generally indicates 
chronic HBV infection. The HBeAg recorded in this 
study showed 4.0%.According to Yang et al, 2002 
the presence of HBeAg in serum indicate active viral 
replication. Zhang et al,(2011) in his studies recorded 
1.6% HBeAg positivity among young adults while 
the rate of positivity decreased with age due to the 
spontaneous seroconversion to the Antibody against 
the HBeAg.  
In the study conducted by Tsai et al,(2008), Liver 
function tests are used to determine if the liver has 
been damaged or its function impaired. Elevations of 
certain liver tests in relation to others aids in that 
determination ALT result showed  abnormality in 
28.0% of the subjects screened. ALT levels have 
been correlated positively with liver inflammation, 
while patients with persistently normal ALT levels 
had significantly lower liver damage compared with 
patients with either intermittent of persistently 
elevated ALT Levels (Zhang et al. 2011).Therefore 
measurement of aminotransferase levels by serial 
observations and analysis remain the most common 
and convenient way to identify liver inflammation in 
patients particularly with chronic HBV infection.  
Conclusion: Prevention is the only safeguard against 
spread of Hepatitis B infection, through avoiding 
practices that increase the risk of exposure to 
infection. Hepatitis B vaccine must be given to high 
risk groups especially the sexually active groups in 
the population. Similarly, Health care workers 
coming in contact with blood and other body Fluids 
should also be meant to undergo full vaccine regimen 
against this infectious agent. Professional and public 
health education and implementation of infection 
control practices in all health facilities should be 
followed up and given prompt attention so as to 
control the spread of Hepatitis B virus in the 
population. 
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